SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to ...

Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...

Effective clearance of apoptotic cells by phagocytes prevents the release of intracellular alarmins and manifestation of autoimmunity. This prompt efferocytosis is complemented by intracellular ...

Patients with cold agglutinin disease (CAD) had durable responses at week 53, and no new safety signals were reported. Newly released data from the CARDINAL study of sutimlimab (Enjaymo) for the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, today announced results from a new, population-based ...

When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a ...

PHOENIX -- The investigational agent riliprubart, a complement C1s inhibitor, showed encouraging activity in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), according to a ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 27 (Jul. 6, 2004), pp. 10127-10131 (5 pages) The lectin complement pathway in innate immunity is closely ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with ...